DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for oligohydramnios — screening already-approved drugs against its 5-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOligohydramnios maps to a 5-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for oligohydramnios is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
inverted formin 2 (INF2) — INF2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9AZP · 3.79 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
A 2000 case report describes a twin pregnancy at 24 weeks where nimesulide, a cyclooxygenase-2 inhibitor, was prescribed for preterm labour prophylaxis. Three weeks later severe oligohydramnios appeared in both sacs despite normal fetal growth, renal anatomy, and Doppler flow. Amniotic fluid volumes returned to normal over two weeks after stopping the drug, with no adverse neonatal renal effects. The authors conclude that selective cyclooxygenase-2 inhibition might cause severe oligohydramnios and advise close fetal surveillance if such drugs are used.
A 2018 review states that oligohydramnios complicates about 1 to 2 percent of pregnancies and increases perinatal morbidity, mortality, and iatrogenic preterm delivery. It lists maternal hydration (oral or intravenous) as the most studied intervention. L-arginine and sildenafil have been supported by several studies, but the review finds no conclusive evidence for them. It specifically recommends against using sildenafil citrate for this purpose until its safety is well established, citing recent reports of adverse fetal outcome.
A 2015 study reports that in 18.0 percent of patients with oligohydramnios, a major contributing factor was a change in maternal blood plasma osmolarity. A 2019 review notes that the pathogenesis of isolated oligohydramnios (oligohydramnios without anatomical, functional, or chromosomal abnormalities) is not clear. It states that some recent studies show molecular biological changes play a role, and that isolated oligohydramnios, unlike oligohydramnios with complications, may not have adverse effects on pregnancy outcomes. The review questions whether obstetric intervention is always necessary in such cases.
What is still missing is a clear understanding of the pathogenesis of isolated oligohydramnios, conclusive evidence for any pharmacological intervention beyond maternal hydration, and adequate safety data for drugs like sildenafil. No adequately powered randomised trials have established a safe and effective drug treatment. Patient stratification by underlying cause (e.g., osmolarity changes versus membrane pathology) is not yet standard in trial design.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Obstetrics and Gynecology · 2000 · 52 citations
Severe oligohydramnios induced by cyclooxygenase-2 inhibitor nimesulide
AbstractBACKGROUND: Cyclooxygenase-2 inhibitors might have fewer adverse fetal effects than conventional nonsteroidal anti-inflammatory drugs that inhibit both isoforms of the enzyme. Although cyclooxygenase-2 is expressed in fetal kidneys, there are no reports of adverse effects in human pregnancy. CASE: A 27-year-old woman, gravida 2, para 0, with a twin pregnancy at 24 weeks' gestation had placement of a cervical cerclage. Nimesulide was prescribed for postoperative preterm labor prophylaxis. Three weeks later, severe oligohydramnios was identified in both sacs, despite normal growth, renal anatomy, and umbilical artery and renal artery Doppler flow velocimetry. After stopping the drug, amniotic fluid volumes returned to normal over 2 weeks. There were no adverse neonatal renal effects. CONCLUSION: Selective cyclooxygenase-2 inhibition might cause severe oligohydramnios. If it is used, we advise close fetal surveillance.
Open Access Journal of Gynecology · 2018 · 5 citations · open access
Evidence Based Management of Oligohydramnios
AbstractBackground: Oligohydramnios, or abnormally decreased amount of amniotic fluid, complicates approximately 1 to 2 percent of pregnancies. It poses a risk to the fetus by contributing to perinatal morbidity and mortality, and due to iatrogenic preterm delivery. An increa se in operative delivery increases the risk to the mother. Oligohydramnios may result from known etiological factors or it may accompany other pregnancy complications. When no etiological factor or association is identified, it is termed “Isolated Oligo hydramnios’. Treatment strategies: This review presents the various treatment options for oligohydramnios in the light of current available evidence. Maternal hydration whether orally or by intravenous route is perhaps the most well studied intervention. Many therapeutic agents have also been tried. Of these, L - arginine and sildenafil have been supported by several studies but conclusive evidence for the same could not be identified Conclusions: In cases of isolated oligohydramnios, therapeutic interventi on is desirable to prolong the pregnancy so as to avoid preterm delivery and to prevent adverse perinatal outcome. Based on present scientific evidence we recommend that oral hydration therapy should be offered to the eligible women. Use of sildenafil citr ate for this purpose cannot be recommended till its safety is well established in view of the recent reports of adverse fetal outcome.
Scientific journals of I.Ya.Gorbachevsky Ternopil State Medical University (I.Ya.Gorbachevsky Ternopil State Medical University) · 2015 · 0 citations · open access
РОЛЬ ДЕЦИДУАЛЬНОЇ ЧАСТИНИ ПЛОДОВИХ ОБОЛОНОК І ОСМОЛЯРНОСТІ ПЛАЗМИ КРОВІ МАТЕРІ В РЕГУЛЯЦІЇ ОБ’ЄМУ НАВКОЛОПЛОДОВИХ ВОД.
AbstractIt was established that in development both in idiopathic oligohydramnios and polyhydramnios an important role had the structural components of decidual membranes and changing osmolarity of mothers blood plasma. Our study proved that 18.0 % of patients with oligohydramnios and 39.0 % in the case of polyhydramnios major factor that contributes to the pathology of amniotic environment was the changе blood plasma of osmolarity.
Pathogenesis and obstetric interventions of isolated oligohydramnios
AbstractReduction of amniotic fluid in late pregnancy is a common complication in clinic. Oligohydramnios without any evidence of anatomical, functional, or chromosomal abnormalities is termed isolated oligohydramnios, whose pathogenesis is not clear. It used to be believed that once oligohydramnios occurred, it would have a negative impact on pregnancy outcome. Therefore, obstetric intervention should be carried out in time to avoid the occurrence of adverse pregnancy outcomes. However, part of pregnant women are still in oligohydramnios after regular treatment. And some recent studies on oligohydramnios have shown that molecular biological changes play a very important role in the occurrence of such diseases. Besides, isolated oligohydramnios, unlike oligohydramnios with complications, do not have adverse effects on pregnancy outcomes. Therefore, further research is needed on whether obstetric intervention should be carried out in such pregnant women. This article reviews the pathogenesis of oligohydramnios in late pregnancy and the progress of obstetrical intervention.
Key words:
Isolated oligohydramnios; APQs; VEGF; Cx43; Obstetrical intervention
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
